Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors

被引：91
作者：
Ghatalia, Pooja [1 ]
Morgan, Charity J. [2 ]
Je, Youjin [3 ]
Nguyen, Paul L. [4 ,5 ]
Quoc-Dien Trinh [4 ,5 ]
Choueiri, Toni K. [4 ,5 ]
Sonpavde, Guru [6 ]
机构：
[1] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL USA
[2] Kyung Hee Univ, UAB Sch Publ Hlth, Dept Biostat, Seoul, South Korea
[3] Kyung Hee Univ, Dept Food & Nutr, Seoul, South Korea
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA USA
[6] UAB Med Ctr, Sect Med Oncol, Dept Internal Med, Birmingham, AL 35233 USA
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2015年 / 94卷 / 02期
关键词：
Vascular endothelial growth factor receptor; Tyrosine kinase inhibitors; Approved; Congestive heart failure; Meta-analysis; PHASE-III TRIAL; DOUBLE-BLIND; 1ST-LINE TREATMENT; CANCER-PATIENTS; SUNITINIB; METAANALYSIS; PLACEBO; SORAFENIB; RISK; PLUS;
D O I：
10.1016/j.critrevonc.2014.12.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A systematic review and meta-analysis was conducted to determine the relative risk (RR) of congestive heart failure (CHIP) associated with approved multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized trials comparing arms with and without an FDA-approved VEGFR TKI. Statistical analyses calculated the relative risk (RR) and 95% confidence intervals (CI). A total of 10,647 patients from 16 phase III trials and 5 phase II trials were selected. All grade CHIP occurred in 138 of 5752 (2.39%) patients receiving VEGFR TKIs and 37 of 4895 (0.75%) patients in the non-TKI group. High-grade CHF occurred in 17 of 1426(1.19%) patients receiving VEGFR TKIs and 8 of 1232(0.65%) patients in the non-TKI group. The RR of all grade and high-grade CHF for the TKI vs. no TKI arms was 2.69 (p<0.001; 95% CI: 1.86 to 3.87) and 1.65 (p=0.227, 95% CI: 0.73 to 3.70), respectively. The RR of relatively specific TKIs (axitinib) was similar to relatively non-specific TKIs (sunitinib, sorafenib, vandetanib, pazopanib). (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：228 / 237
页数：10
相关论文
共 50 条
[31]   Thyroid dysfunction related to vascular endothelial growth factor receptor tyrosine kinase inhibitors: A real-world study based on FAERS [J].
Liao, Xiaolan ;
Liu, Zhihong ;
Song, Hongtao .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (05) :1418-1425
[32]   Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa? [J].
Boers-Sonderen, Marye J. ;
Mulder, Sasja F. ;
Nagtegaal, Iris D. ;
Derikx, Lauranne A. A. P. ;
Wanten, Geert J. A. ;
Mulders, Peter F. A. ;
van der Graaf, Winette T. A. ;
Hoentjen, Frank ;
van Herpen, Carla M. L. .
ACTA ONCOLOGICA, 2016, 55 (04) :444-448
[33]   Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis [J].
Xue, Yifei ;
Feng, Shuo ;
Li, Guangyao ;
Zhang, Chao .
FRONTIERS IN PHARMACOLOGY, 2023, 14
[34]   Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition Effects on Renal Function [J].
Boursiquot, Brian C. ;
Zabor, Emily C. ;
Glezerman, Ilya G. ;
Jaimes, Edgar A. .
HYPERTENSION, 2017, 70 (03) :552-558
[35]   Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials [J].
Qi, W. -X. ;
Tang, L. -N. ;
Sun, Y. -J. ;
He, A. -N. ;
Lin, F. ;
Shen, Z. ;
Yao, Y. .
ANNALS OF ONCOLOGY, 2013, 24 (12) :2943-2952
[36]   Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis [J].
Li, Jing ;
Gu, Jian .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) :807-816
[37]   High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor [J].
Pouessel, Damien ;
Culine, Stephane .
EUROPEAN UROLOGY, 2008, 53 (02) :376-381
[38]   Vascular endothelial growth factor-tyrosine kinase inhibitors: Novel mechanisms, predictors of hypertension and management strategies [J].
Gomez, Javier A. .
AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2022, 17
[39]   Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors [J].
Park, Inkeun ;
Cho, Yong Mee ;
Lee, Jae-Lyun ;
Ahn, Jin-Hee ;
Lee, Dae-Ho .
TUMOR BIOLOGY, 2016, 37 (04) :4919-4927
[40]   Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis [J].
Lin, Zexin ;
Yang, Yilin ;
Huang, Yongliang ;
Liang, Junjie ;
Lu, Fang ;
Lao, Xuejun .
MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (04) :959-967
12345